STOCK TITAN

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Revelation Biosciences CEO to present at 2023 ROTH Healthcare Opportunities Conference on Oct 12. One-on-one investor meetings scheduled.
Positive
  • None.
Negative
  • None.

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming 2023 ROTH Healthcare Opportunities Conference being held in New York, NY on October 12, 2023. Mr. Rolke will also be participating in one-on-one investor meetings at the conference.

Roth 2023 Healthcare Opportunities Conference

Date:

Thursday, October 12, 2023

Time:

8:45 a.m. Eastern Time

Location:

Tap Room - 3rd Floor @ The Yale Club, New York, NY

Register:

https://www.meetmax.com/sched/event_95633/conference_register.html

Please contact your ROTH representative to schedule one-on-one meetings with the management team during the conference.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. Revelation’s product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD) and its well-established effect on the innate immune system. Our two lead programs include evaluating Gemini as a potential therapy for the treatment of acute and chronic organ disease including acute kidney injury (AKI), chronic kidney disease (CKD) and myocarditis (REVTx-300) and as a potential prevention and treatment of hospital acquired infection (REVTx‑100).

For more information on Revelation, please visit www.RevBiosciences.com.

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences, Inc.

Email: svedrick@revbiosciences.com

and

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences, Inc.

Email: czygmont@revbiosciences.com

Source: Revelation Biosciences Inc.

Revelation Biosciences, Inc.

NASDAQ:REVB

REVB Rankings

REVB Latest News

REVB Stock Data

3.87M
1.63M
0.32%
1.96%
2.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About REVB

we develop immunologic therapeutics and diagnostics designed to make the world a healthier place